Accumulation of cerebral amyloid ␤-protein (A␤) is believed to be part of the pathogenic process in Alzheimer's disease. A␤ is derived by proteolytic cleavage from a precursor protein, the amyloid precursor protein (APP). APP is a type-1 membrane-spanning protein, and its carboxyl-terminal intracellular domain binds to X11␤, a neuronal adaptor protein. X11␤ has been shown to inhibit the production of A␤ in transfected non-neuronal cells in culture. However, whether this is also the case in vivo in the brain and whether X11␤ can also inhibit the deposition of A␤ as amyloid plaques is not known. Here we show that transgenic overexpression of X11␤ in neurons leads to a decrease in cerebral A␤ levels in transgenic APPswe Tg2576 mice that are a model of the amyloid pathology of Alzheimer's disease. Moreover, overexpression of X11␤ retards amyloid plaque formation in these APPswe mice. Our findings suggest that modulation of X11␤ function may represent a novel therapeutic approach for preventing the amyloid pathology of Alzheimer's disease. X11␤ (also known as munc-18-interacting protein-2; mint-2) is a neuronal adaptor protein involved in the formation of multiprotein complexes in the brain. To fulfill this function, X11␤ contains a number of protein-protein interaction domains through which it binds specific ligands. These include aminoterminal sequences that bind munc-18 and a novel protein XB51 (1-3), two carboxyl-terminal PDZ domains that bind presenilin-1 (4, 5), neurexins (6), and NF-B/p65 (7), and a centrally located PTB domain that binds to the Alzheimer's disease amyloid precursor protein (APP) 1 (8 -11). APP is a type-1 membrane protein that is proteolytically processed to produce secreted derivatives, and one of these is the 40 -42-amino-acid A␤ peptide that is deposited within amyloid plaques in the brains of patients with Alzheimer's disease.
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X11␤ (also known as munc-18-interacting protein-2; mint-2) is a neuronal adaptor protein involved in the formation of multiprotein complexes in the brain. To fulfill this function, X11␤ contains a number of protein-protein interaction domains through which it binds specific ligands. These include aminoterminal sequences that bind munc-18 and a novel protein XB51 (1-3), two carboxyl-terminal PDZ domains that bind presenilin-1 (4, 5) , neurexins (6) , and NF-B/p65 (7) , and a centrally located PTB domain that binds to the Alzheimer's disease amyloid precursor protein (APP) 1 (8 -11) . APP is a type-1 membrane protein that is proteolytically processed to produce secreted derivatives, and one of these is the 40 -42-amino-acid A␤ peptide that is deposited within amyloid plaques in the brains of patients with Alzheimer's disease.
Cleavage of APP to release A␤ involves sequential proteolysis by ␤-secretase (BACE1) and ␥-secretase (presenilin/nicastrin/ Aph-1/Pen-2); alternative cleavage by ␣-secretase within the A␤ sequence precludes A␤ production (12) (13) (14) . Aberrant processing of APP leading to the increased production of A␤ is believed to contribute to Alzheimer's disease. In particular, the increased production of the longer A␤ species is thought to be an early pathogenic event in Alzheimer's disease (13) .
X11␤ is part of a small family of related proteins that also include X11␣ and X11␥; X11␤ and X11␣ are neuronal (15) . Both X11␣ and X11␤ inhibit the production of A␤ in transfected non-neuronal cells (16 -18) , and recently, X11␣ has been shown to inhibit the production and deposition of A␤ in the brains of transgenic mice (19) . However, similar in vivo transgenic studies have not been performed for X11␤, and this represents a major omission. This is because neurons can process APP to produce A␤ differently from cell lines in culture (20 -23) and because the deposition of A␤ can only be studied properly in vivo in the brain.
Likewise, it is important to study the effects of both X11␤ and X11␣ on A␤ production since they are different gene products with different functions and since the mechanisms by which they modulate APP processing are now known to have quite distinct aspects. For example, X11␤ and X11␣ have different binding partners, and these interacting proteins are known to influence the effect of the X11s on A␤ production; X11␣ but not X11␤ binds to CASK, whereas X11␤ binds to NF-B/p65, XB51, and alcadein (1, 3, 7, 24, 25) . NF-B/p65, XB51, and alcadein all function in X11␤-mediated inhibition of A␤ production (3, 7, 24, 25) . Also, phosphorylation of Thr 668 in APP by JNK family kinases is believed to modulate APP processing and A␤ production, and recently, X11␤ but not X11␣ has been shown to regulate phosphorylation of this residue by JNKs (26 -28) . Finally, X11␣ inhibits the production of both A␤ and A␤(1-42) species in transfected cells (16 -18) , whereas X11␤ selectively inhibits only A␤(1-40) production (9) . Thus, understanding the roles of the X11s on A␤ production in the brain requires analyses of both X11␣ and X11␤.
To properly address the role of X11␤ in A␤ production and deposition in the brain, we have therefore created X11␤ transgenic mice and crossed these with APP transgenic 2576 mice that harbor the familial Alzheimer's disease Swedish mutation (APPswe Tg2576 mice) (29) . These APPswe Tg2576 mice have increased levels of both A␤ and A␤(1-42) species, develop amyloid plaques, and are one of the best characterized models of Alzheimer's disease amyloidosis. Our results show that X11␤ inhibits the production and deposition of A␤ in these animals.
EXPERIMENTAL PROCEDURES

Construction of Transgenic
Mice-A carboxyl-terminal Myc-tagged full-length mouse X11␤ cDNA (10) was cloned into a modified mouse prion gene in which the single exon encoding the prion protein was deleted and engineered to contain a unique XhoI site (30) . Vector sequences were removed, and the construct was injected into C57Bl6/ SJL embryos (Xenogen Biosciences, Cranbury, NJ). Founder mice were crossed with C57Bl/6 animals, and offspring were backcrossed a further three times onto this background prior to analyses. APPswe Tg2576 mice (29) were obtained from Taconic Farms, Germantown, NY and bred by mating male mice with C57Bl6/SJL F1 females as recommended by the suppliers and as described by others (31) . For crossing of X11␤ and APPswe lines, male APPswe Tg2576 animals were mated with female X11␤ mice.
Northern Analyses-RNA was prepared using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. RNA samples were quantified by spectrophotometric analysis, and their integrity was confirmed by observing 28 and 18 S ribosomal species following electrophoresis in denaturing 1% agarose gels in MOPS buffer (40 mM MOPS, 10 mM sodium acetate, 1 mM EDTA, pH 7.2) containing 2% formaldehyde. For Northern blotting, 20 g of each sample were separated as above and transferred to GeneScreen Plus membranes (PerkinElmer Life Sciences). Probes were labeled with [␥-32 P]dCTP by random priming using a Prime-It II kit (Stratagene). APP mRNA was detected using a full-length human APP cDNA probe, and ␤-actin was detected with a commercial probe (Clontech). Hybridizations, washings, and autoradiography were performed as described previously (10) .
SDS-PAGE and Immunoblotting-Mouse brains were weighed and prepared as 10%(w/v) homogenates in ice-cold 125 mM Tris-HCl (pH 6.8), 5 mM EDTA, 5 mM EGTA plus Complete protease inhibitor mixture (Roche Applied Science). A one-quarter volume of 10% SDS sample buffer was then added, and the samples were heated in a boiling water bath for 10 min. Protein concentrations were determined using Markwell assays.
Samples were separated on 8 or 10% (w/v) acrylamide gels and transferred to Protran nitrocellulose membranes (Schleicher & Schuell) using a Bio-Rad TransBlot system. APP carboxyl-terminal fragments were separated on 10% (w/v) Tris-Tricine gels. The blots were probed with primary antibodies, washed in phosphate-buffered saline, and incubated with horseradish peroxidase-conjugated anti-mouse or antirabbit Igs (Amersham Biosciences). Blots were developed using an enhanced chemiluminescence system (Amersham Biosciences) according to the manufacturer's instructions. X11␤ was detected using a rabbit polyclonal antibody (10) that detects both human and mouse X11␤ with equal sensitivity or mouse monoclonal antibody 9B11 (Cell Signaling Technology) to the Myc tag on the carboxyl terminus of transgenic X11␤. APP was detected using a rabbit polyclonal antibody generated using a synthetic peptide to the last 21 amino acid residues of APP (4).
To calculate the relative amounts of APP in the different mouse brain samples, increasing amounts (2.5-40 g) of total brain proteins were probed for APP on immunoblots, and the signals were then quantified by pixel densitometry using a Bio-Rad GS710 imaging densitometer and Quantity 1 software as described (32) . From these data, standard curves were generated so as to demonstrate that the protein amounts loaded on the gels gave APP signals on the immunoblots that were within the linear range. Carboxyl-terminal APP fragments were quantified in a similar manner.
Immunohistochemical Analyses-Brains from X11␤ transgenic mice and from mice derived from APPswe ϫ X11␤ crosses were analyzed by immunostaining essentially as described previously (19) . X11␤ was detected using a rabbit X11␤ polyclonal antibody (10) or mouse monoclonal antibody 9B11 antibody to the Myc tag on the transgene; A␤ deposits were detected using antibody 1E8 (33) . To quantify the number of A␤ deposits, 10-m serial coronal sections were cut through the cortex/hippocampal regions of each mouse, and every 10th section was analyzed so that each section was separated from its neighbor by ϳ100 m. Two individuals counted the plaques; one scored plaque numbers in all of the mice, whereas a second individual counted plaques in half of the mice to confirm the results. Plaques were counted "blind" without knowledge of the genotype of the mouse. Images were captured on a Zeiss Axioscope 2 MOT using an Axiocam and Axiovision software (Zeiss, Welwyn Garden City, UK). Diameters of plaques were determined using Metamorph image analysis software as described (19) .
A␤ Assays-A␤ species were assayed using commercial enzymelinked immunosorbent assay kits and following the manufacturers' instructions. A␤(1-40) was assayed using human amyloid ␤(1-40)-(N) enzyme-linked immunosorbent assay (IBL), and A␤(1-42) was detected using Innotest ␤-amyloid(1-42) enzyme-linked immunosorbent assay (Innogenetics). Brain samples were prepared for assay by homogenization as 20% homogenates in 20 mM Tris-HCl, pH 8.0, containing 5 mM EDTA plus Complete protease inhibitor mixture (Roche Applied Science) (assay buffer) using a Dounce homogenizer. Thereafter, the samples were spun at 100,000 ϫ g for 1 h, and the supernatant containing soluble A␤ was then removed and diluted as appropriate in assay buffer for analyses (Tris-HCl-soluble A␤). To assay for insoluble A␤, the remaining pellet was extracted as a 15% homogenate in 70% formic acid by sonication at level 4 for 35 s using a Vibra cell disruptor (Sonic & Materials Inc.); the mixture was then spun at 100,000 ϫ g for 1 h, and the supernatant was removed and diluted 1:20 with 1 M Tris to neutralize the pH. The samples were then diluted as appropriate in assay buffer for analyses (formic acid-soluble A␤). Data was analyzed by one way analysis of variance tests.
RESULTS
We constructed X11␤ transgenic mice using the mouse prion promoter and regulatory elements to drive expression (30) . These elements direct expression to the brain and have been used to create a number of transgenic mouse lines expressing Alzheimer's disease-related proteins (34 -36) . To facilitate the detection of transgenic X11␤ protein, we placed a Myc epitope tag on its carboxyl terminus.
We obtained three X11␤ transgenic founder mice, two of which (lines 34 and 42) transmitted the transgene to offspring and were analyzed in more detail. These mice bred well and did not appear different from their non-transgenic littermates. Probing of immunoblots with antibody 9B11 that detects the Myc tag revealed that transgenic X11␤ protein was expressed in the brain of both transgenic lines, and probing of similar blots with an X11␤ antibody confirmed these results (Fig. 1) . Analyses of the signals obtained from transgenic and nontransgenic samples by densitometry revealed that X11␤ was overexpressed 7-fold in the brains of both transgenic lines.
We next analyzed expression of transgenic X11␤ by immunostaining of brain sections with antibody 9B11 to the Myc tag. These studies demonstrated that transgenic X11␤ was expressed in an identical fashion in both transgenic lines and that it was located within neurons in a diverse number of brain regions. There was no obvious expression in cells with glial morphology. Neuronal populations expressing transgenic X11␤ included those within the neocortex, hippocampus, and Purkinje cells of the cerebellum (Fig. 2) . Myc immunoreactivity was most prominent in cell bodies and proximal dendrites. These findings are similar to those described for expression of endogenous X11␤ in the brain, where it, too, is present in the somatodendritic compartment of a wide variety of neuronal subtypes (5, 10, 37) . Thus, the expression pattern of transgenic X11␤ broadly mimics that of the endogenous protein.
To investigate the effect that overexpression of X11␤ has on APP and A␤ production within the brain, we crossed each of the X11␤ transgenic lines with transgenic mice expressing a familial Alzheimer's disease mutant APP harboring the double K670N/M671L Swedish mutation (transgenic APPswe mice line Tg2576). These APPswe mice secrete increased levels of human A␤ and A␤(1-42) and develop A␤ amyloid plaques similar to those seen in the brains of patients with Alzheimer's disease (29) . This approach of crossing Alzheimer's disease mutant APP mice with other transgenics to investigate the effect of a particular transgene on A␤ production has now been utilized in a number of studies. These include investigating the effects of presenilin 1, ␤-secretase, and insulin-degrading enzyme on A␤ production (Refs. 38 -43 and see reviews in Refs. 44 and 45) . Analyses of the offspring derived from these crosses revealed that their genotypes approximated that expected of Mendelian inheritance ( 1 ⁄4 of each non-transgenic, APPswe transgenic, X11␤ transgenic, APPswe/X11␤ double transgenic). There was no evidence of any gross abnormal phenotype in any of the mice.
We then studied whether overexpression of X11␤ influenced the levels of APP mRNAs and proteins in the brains of the mice. Northern blotting revealed that X11␤ had no detectable effect on the steady-state levels of either endogenous mouse or transgenic human APP mRNAs (Fig. 3) . To determine whether overexpression of X11␤ influenced APP holoprotein levels, we performed quantitative immunoblots for APP on the different brain samples (Fig. 4) . We first generated standard curves for APP signal on the blots, and by loading the amounts of protein (10 g ) that fell within the linear range for this signal, we analyzed the relative APP levels in the different mice generated from the various crosses. Statistical analyses of these data by one-way analysis of variance revealed that X11␤ had no effect on the steady-state levels of either endogenous mouse or transgenic human APP protein (all data not shown, but Fig. 4 shows examples of signals obtained from non-transgenic, APPswe, X11␤, and APPswe/X11␤ transgenic mice).
We next compared the levels of human A␤(1-40) and A␤ in the brains of APPswe and APPswe/X11␤ transgenic littermates. APPswe Tg2576 mice have elevated levels of A␤, but in young mice, these levels are relatively low, and the A␤ species are mainly soluble in aqueous buffers (Tris-HCl-soluble A␤). However, as mice age, A␤ levels increase exponentially and shift to a fraction that requires extraction with formic acid for solubilization (formic acid-soluble A␤). These changes in solubility occur at ϳ6 months of age with the deposition of A␤ in amyloid plaques beginning 2 months later (31). In the first instance, we therefore compared A␤ levels in young (10 -12-week-old) mice. Both A␤(1-40) and A␤(1-42) species were present within the Tris-HCl-soluble fraction at this age with levels of formic acid-soluble A␤ being below the level of accurate detection (data not shown); these findings are consistent with previous observations on APPswe Tg2576 mice (31) . However, in both sets of crosses, we observed a marked 20 -24% reduction in A␤(1-40) levels in APPswe/X11␤ double transgenics when compared with APPswe-only littermates. We did not detect any changes in the levels of A␤(1-42) species in the presence of X11␤ in either line (Fig. 5A ). This may be partly due to the very low levels of A␤ in the brains of APPswe mice at this age. Thus, in two independent transgenic lines, overexpression of X11␤ lowers the levels of A␤ in the brains of APPswe Tg2576 mice.
We next analyzed A␤ levels in 10-month-old mice derived from APPswe and X11␤ (line 42) matings. 10 months is a key time point in the development of amyloid pathology in the APPswe Tg2576 mice. At this age, the levels of both A␤ and A␤(1-42) have increased by over 100-fold, a significant proportion of A␤ has shifted to the insoluble (formic acidsoluble) fraction, and A␤ plaques are clearly detectable within the brain. The levels of both Tris-HCl-soluble and formic acidsoluble A␤ species were significantly reduced in APPswe/X11␤ double transgenics when compared with APPswe littermates. Tris-HCl-soluble A␤(1-40) and A␤(1-42) were reduced by 35 and 16%, respectively; formic acid-soluble A␤(1-40) and A␤ were reduced by 18 and 45%, respectively (Fig. 5B) .
We also examined whether X11␤ inhibits the deposition of A␤ in amyloid plaques in the brain by counting A␤ immunolabeled deposits in 10-month-old APPswe and APPswe/X11␤ littermates. X11␤ induced a significant 51% reduction in the number of A␤ deposits in the brain (Fig. 6) . We also compared the size of plaques in APPswe and APPswe/X11␤ double transgenic mice and discovered that the mean diameter of plaques was significantly reduced in the APPswe/X11␤ animals (mean diameter of plaques in APPswe mice, 34.2 m; mean diameter of plaques in APPswe/X11␤ mice, 20.6 m). Thus, X11␤ significantly lowers the levels of both soluble and insoluble A␤ and A␤(1-42) species, and this leads to a marked reduction in the number of amyloid plaques in APPswe 10-month-old transgenic mice.
To gain insight into the mechanisms by which X11␤ might influence APP processing and A␤ production, we compared the production of APP carboxyl-terminal fragments produced by ␣-and ␤-secretases in APPswe and APPswe/X11␤ mice. We detected no difference in the amounts of these products in the two sets of mice (Fig. 7) . We have previously shown that X11␤ is associated with neuritic plaques in Alzheimer's disease brains, where it is found within the corona of dystrophic neurites surrounding the amyloid deposit (10) . We therefore inquired whether X11␤ displayed similar co-localization with A␤ deposits in the APPswe and APPswe/X11␤ mice. Immunostaining of adjacent sections for A␤ and X11␤ (using either an X11␤ antibody or antibody 9B11 to the Myc tag on transgenic X11␤) revealed that X11␤ was closely associated with the larger A␤ deposits in both sets of mice, although labeling was much weaker around smaller deposits (Fig. 6) . Analyses of the formic acid-soluble fraction that contains insoluble A␤ by immunoblotting revealed the presence of X11␤ (data not shown).
DISCUSSION
The X11s are a family of adaptor proteins comprising three members, X11␣, X11␤, and X11␥, that all bind to the carboxyl terminus of APP (8, 9, 11, 18, 46 -49) . X11␣ and X11␤ are neuron-specific, whereas X11␥ is ubiquitously expressed (9, 10, 49 -52). X11␣ has been shown to inhibit A␤ secretion (16 -19) , and here we demonstrate that X11␤ reduces the levels of A␤ in the brains of APPswe Tg2576 mice. In particular, we see a marked reduction in soluble A␤(1-40) species in young 10 -12-week-old X11␤ mice and a reduction in both soluble and insoluble A␤ and A␤(1-42) species in 10-month-old mice. At 10 months of age, A␤ amyloid plaques are clearly detectable in APPswe Tg2576 mice, and we also observe a significant reduction in plaque numbers in mice overexpressing X11␤. Thus, X11␤ lowers the levels of both A␤(1-40) and A␤ , and this leads to a reduction in the numbers of amyloid plaques in the brains of APPswe mice.
In transfected non-neuronal cells, X11␣ inhibits the production of A␤ and A␤(1-42) species (16 -18) , whereas X11␤ inhibits only A␤(1-40) production (9) . However, others have not observed such a selective effect on A␤(1-40) by X11␤ (16) , and indeed, X11␤ inhibits both A␤(1-40) and A␤(1-42) production in cells expressing the carboxyl-terminal 99 amino acids of APP (24) . In our X11␤ transgenic mice, the levels of both A␤(1-40) and A␤(1-42) are reduced, and so, in vivo, X11␤ inhibits the production of both species in the brain. The reasons for these different findings between transfected non-neuronal cells and transgenic mice are unclear. However, there is evidence that neurons process APP differently from other cell types (20 -23, 53) . Thus, the different results may simply be a consequence of the different experimental systems (transfected non-neuronal cells versus transgenic mice) that have been used in these studies.
The mechanisms by which X11␤ inhibits A␤ production are unclear, although the finding that the X11s stabilize full-length APP suggests that they may somehow inhibit APP processing (5, 10, 16, 17) . One suggestion is that X11␤ binds to NF-B/p65 so as to suppress the ability of NF-B to induce expression of proteins involved in A␤ production (7) . Alternatively, two groups have demonstrated that both X11␣ and X11␤ interact with presenilin-1, one of the major components of ␥-secretase (4, 5), and recently, X11␣ has been shown to impair ␥-secretase (but not ␣-or ␤-secretase) activity in cultured non-neuronal cells (54) . Likewise, we observed no differences in ␣-and ␤-secretase-derived APP carboxyl-terminal fragments in our APPswe and APPswe/X11␤ transgenic mice, and this lends strong support to the notion that the X11s exert their inhibitory effect on A␤ production by specifically reducing ␥-secretase cleavage of APP. One suggestion is that this inhibition is via altering APP/presenilin-1 trafficking in some way (54) .
Whatever the precise mechanisms by which X11␤ influences APP processing, our results demonstrate that altering its expression can reduce A␤ levels and A␤ deposition in vivo in the brain. As such, modulation of X11␤ function may represent a novel therapeutic strategy for Alzheimer's disease. 
